Literature DB >> 7867889

Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle.

M L Villanueva-Peñacarrillo1, A I Alcántara, F Clemente, E Delgado, I Valverde.   

Abstract

GLP-1(7-36)amide is an intestinal post-translational proglucagon product released mainly after carbohydrate ingestion, the glucose dependent insulinotropic and antidiabetogenic actions of which have been documented. In this work, by exploring whether GLP-1(7-36)amide has any effect on the glucose metabolism of the muscle, we have observed that this peptide, at physiological concentrations, exerts in this tissue an increment of the D-[U-14C]glucose incorporated into glycogen, which is accompanied by an increase in the glycogen synthase a activity; also, it stimulates both glucose oxidation and lactate formation. These data indicate that the skeletal muscle is one of the target tissues for GLP-1(7-36)amide, where its insulin-like effect explains, at least in part, its plasma glucose lowering action; thus, GLP-1(7-36)amide may well be implicated in the physiological control of glucose homeostasis after meals, not only by acting as an incretin, but also by directly promoting glucose disposal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7867889     DOI: 10.1007/bf00418382

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

1.  The effects of glucose and of potassium ions on the interconversion of the two forms of glycogen phosphorylase and of glycogen synthetase in isolated rat liver preparations.

Authors:  L Hue; F Bontemps; H Hers
Journal:  Biochem J       Date:  1975-10       Impact factor: 3.857

2.  Modulation by a sulfonylurea of insulin-dependent glycogenesis, but not of insulin binding, in cultured rat hepatocytes. Evidence for a postreceptor mechanism of action.

Authors:  W E Fleig; G Noether-Fleig; R Fussgaenger; H Ditschuneit
Journal:  Diabetes       Date:  1984-03       Impact factor: 9.461

3.  Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C.

Authors:  M B Wheeler; M Lu; J S Dillon; X H Leng; C Chen; A E Boyd
Journal:  Endocrinology       Date:  1993-07       Impact factor: 4.736

4.  Regulation of glycogen synthase activity in the isolated mouse soleus muscle. Effect of insulin, epinephrine, glucose and anti-insulin receptor antibodies.

Authors:  Y Le Marchand-Brustel; P Freychet
Journal:  Biochim Biophys Acta       Date:  1981-09-18

Review 5.  Glucagon-like peptide-1, a new hormone of the entero-insular axis.

Authors:  C Orskov
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

6.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Authors:  B Thorens
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

7.  Decreased basal, noninsulin-stimulated glucose uptake and metabolism by skeletal soleus muscle isolated from obese-hyperglycemic (ob/ob) mice.

Authors:  G S Cuendet; E G Loten; B Jeanrenaud; A E Renold
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

8.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

Authors:  M Gutniak; C Orskov; J J Holst; B Ahrén; S Efendic
Journal:  N Engl J Med       Date:  1992-05-14       Impact factor: 91.245

9.  Relationship between D-glucose oxidation and glycolysis in tumoral pancreatic islet cells with either rapid or decreased cell growth.

Authors:  J Camara; C Galera; I Valverde; W J Malaisse
Journal:  Diabetes Res       Date:  1991-06
  9 in total
  21 in total

1.  GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.

Authors:  C G Jolivalt; M Fineman; C F Deacon; R D Carr; N A Calcutt
Journal:  Diabetes Obes Metab       Date:  2011-11       Impact factor: 6.577

Review 2.  Brain GLP-1 and insulin sensitivity.

Authors:  Darleen Sandoval; Stephanie R Sisley
Journal:  Mol Cell Endocrinol       Date:  2015-02-24       Impact factor: 4.102

3.  Glucagon-like peptide-1(7-36) amide and glycogen synthesis in the liver.

Authors:  Y Nakagawa; K Kawai; H Suzuki; S Ohashi; K Yamashita
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

Review 4.  GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side.

Authors:  Brad P Dieter; Radica Z Alicic; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2018-08-15

5.  Therapeutic vaccine against DPP4 improves glucose metabolism in mice.

Authors:  Zhengda Pang; Hironori Nakagami; Mariana K Osako; Hiroshi Koriyama; Futoshi Nakagami; Hideki Tomioka; Munehisa Shimamura; Hitomi Kurinami; Yoichi Takami; Ryuichi Morishita; Hiromi Rakugi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

6.  Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver.

Authors:  M A Trapote; F Clemente; C Galera; M Morales; A I Alcántara; M I López-Delgado; M L Villanueva-Peñacarrillo; I Valverde
Journal:  J Endocrinol Invest       Date:  1996-02       Impact factor: 4.256

7.  Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance.

Authors:  Kim A Sjøberg; Stephen Rattigan; Jacob F Jeppesen; Anne-Marie Lundsgaard; Jens J Holst; Bente Kiens
Journal:  J Physiol       Date:  2015-03-19       Impact factor: 5.182

8.  Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models.

Authors:  M L Villanueva-Peñacarrillo; J Puente; A Redondo; F Clemente; I Valverde
Journal:  Endocrine       Date:  2001-07       Impact factor: 3.633

9.  Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle.

Authors:  C Fürnsinn; K Ebner; W Waldhäusl
Journal:  Diabetologia       Date:  1995-07       Impact factor: 10.122

10.  Incretin concepts.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.